Join
Live feed
·
PRReleasevia Quantisnow
Corbus Pharmaceuticals Holdings Inc. logo

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

ByQuantisnow·Wall Street's wire, on your screen.
CRBP· Corbus Pharmaceuticals Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRBP (Corbus Pharmaceuticals Holdings Inc.) and more on Quantisnow.